Difficulty: Medium
Average Score: 92%
Testbank
When used for treatment of patients diagnosed with Alzheimer's disease, which medication would be expected to antagonize N-methyl-D-aspartate (NMDA) channels rather than cholinesterase?
Correct answer
C
Rationale
Memantine antagonizes N-methyl-D-aspartate (NMDA) channels, making it the appropriate choice for treating Alzheimer's disease in this context. Memantine works by regulating glutamate activity, which is crucial in preventing excitotoxicity associated with Alzheimer's, distinguishing it from cholinesterase inhibitors that increase acetylcholine levels.
A: Donepezil increases acetylcholine levels by inhibiting cholinesterase, but it does not affect NMDA channels, making it unsuitable for this specific question.
B: Rivastigmine also inhibits cholinesterase to enhance acetylcholine, failing to address the NMDA channel antagonism required by the stem.
D: Galantamine, similar to Donepezil and Rivastigmine, primarily acts as a cholinesterase inhibitor and does not antagonize NMDA channels.
A: Donepezil increases acetylcholine levels by inhibiting cholinesterase, but it does not affect NMDA channels, making it unsuitable for this specific question.
B: Rivastigmine also inhibits cholinesterase to enhance acetylcholine, failing to address the NMDA channel antagonism required by the stem.
D: Galantamine, similar to Donepezil and Rivastigmine, primarily acts as a cholinesterase inhibitor and does not antagonize NMDA channels.